Makers Laboratories Ltd Downgraded to Sell Amid Valuation and Financial Concerns

Quality Assessment: Weak Long-Term Fundamentals Weigh on Outlook

Makers Laboratories’ quality grade remains subdued, reflecting its weak long-term fundamental strength. Over the past five years, the company has experienced a negative compound annual growth rate (CAGR) of -7.99% in operating profits, indicating a persistent decline in core profitability. This trend is concerning for investors seeking sustainable earnings growth in the pharmaceutical sector.

Return on Equity (ROE), a critical measure of profitability relative to shareholders’ funds, stands at a modest 3.22% for the latest period, with an average ROE of 4.67% over recent years. Such low returns suggest limited efficiency in generating profits from equity capital, which is a key factor in the quality downgrade. Despite this, the company’s Return on Capital Employed (ROCE) is relatively stronger at 15.26%, indicating some operational efficiency in asset utilisation.

While the company’s promoters maintain majority ownership, the weak profitability metrics and declining operating profit trend have constrained the overall quality rating, contributing to the cautious stance reflected in the Mojo Grade.

Valuation: Downgrade from Attractive to Fair Amid Elevated Price Multiples

The most significant trigger for the downgrade to Sell is the change in valuation grade from attractive to fair. Makers Laboratories currently trades at a price-to-earnings (PE) ratio of 38.16, which is considerably higher than some of its peers such as Venus Remedies (PE 18.04) and Fermenta Biotec (PE 19.4), though lower than others like Shukra Pharma (PE 52.23) and NGL Fine Chem (PE 40.96).

Other valuation multiples include a price-to-book (P/B) value of 1.23, which is modest but not compellingly cheap, and an enterprise value to EBITDA (EV/EBITDA) ratio of 5.68, suggesting a fair market price relative to earnings before interest, tax, depreciation, and amortisation. The EV to EBIT ratio stands at 8.20, while EV to capital employed is 1.25, both indicating moderate valuation levels.

Notably, the PEG ratio is reported as zero, which may reflect either a lack of earnings growth or data limitations, further complicating valuation assessment. Dividend yield data is unavailable, which removes a potential income consideration for investors.

Compared to its peers, Makers Labs’ valuation is now considered fair rather than attractive, signalling that the stock no longer offers a compelling price advantage. This shift has been a key factor in the downgrade decision, as investors may find better value elsewhere in the sector.

Financial Trend: Mixed Signals with Positive Quarterly Performance but Weak Long-Term Growth

Financially, Makers Laboratories has delivered some encouraging quarterly results for Q4 FY25-26. The company reported its highest quarterly net sales at ₹35.75 crores and a peak PBDIT of ₹5.27 crores. Additionally, the debtors turnover ratio for the half-year period reached a high of 7.08 times, indicating efficient receivables management.

Despite these short-term positives, the longer-term financial trend remains a concern. The company’s operating profits have declined at a CAGR of -7.99% over five years, and profits have fallen by 71.7% over the past year. This stark contraction in profitability undermines confidence in sustained earnings growth.

Stock price performance has been mixed as well. While Makers Labs has outperformed the Sensex over the past week (+1.30% vs. Sensex -1.12%) and month (+2.99% vs. Sensex -0.34%), its year-to-date return of 28.40% significantly outpaces the Sensex’s negative 9.84%. However, over the last year, the stock has declined marginally by -0.52%, underperforming the Sensex’s -5.68% return. Longer-term returns over five years have been disappointing at -30.94%, compared to the Sensex’s robust 46.13% gain.

Technicals: Positive Momentum but Limited by Micro-Cap Status

From a technical perspective, Makers Laboratories shows some signs of positive momentum. The stock’s current price of ₹151.70 is slightly above the previous close of ₹149.70, with intraday highs reaching ₹154.80. The 52-week trading range spans ₹109.00 to ₹186.70, indicating moderate volatility.

Despite this, the company’s micro-cap classification limits liquidity and broader market participation, which can amplify price swings and increase risk. The Mojo Score of 47.0 and the downgrade to Sell reflect a cautious technical outlook, suggesting that while short-term price action is positive, it is insufficient to offset fundamental and valuation concerns.

Conclusion: Valuation Concerns Overshadow Mixed Financial and Technical Signals

Makers Laboratories Ltd’s downgrade from Hold to Sell by MarketsMOJO is primarily driven by a shift in valuation grade from attractive to fair, reflecting elevated price multiples relative to earnings and book value. While the company has demonstrated some positive quarterly financial performance and technical momentum, its weak long-term profitability trends and modest returns on equity weigh heavily on the overall investment thesis.

Investors should note the company’s micro-cap status, which may introduce additional volatility and liquidity risks. The stock’s recent price appreciation has outpaced the broader Sensex in the short term, but longer-term returns remain disappointing. Given these factors, the Sell rating and Mojo Score of 47.0 suggest caution for current and prospective shareholders.

For those invested in the Pharmaceuticals & Biotechnology sector, it may be prudent to consider alternative opportunities with stronger fundamentals and more attractive valuations.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today